Odyssey Health, Inc.
For the period ended Jan 31, 2025. Filed Mar 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jan 31, 2025 · Filed Mar 14, 2025
ODYYStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months Ended January 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $(1,239,032) | $12,739,531 |
| Adjustments to reconcile net income (loss) to net cash flows used in operating activities: | ||
| Amortization | – | 1,538 |
| Stock-based compensation | 96,618 | 1,000,119 |
| Financing costs paid via issuance of common stock | – | 8,750 |
| Amortization of debt discount and closing costs | 31,831 | 219,258 |
| Allowance for research and development rebut due | 22,625 | – |
| Unrealized losses on investment | 370,698 | 1,332,980 |
| Gain on sale of asset | – | (16,400,687) |
| Changes in operating assets and liabilities: | ||
| (Increase) decrease in prepaid expenses and other current assets | (69,235) | 21,742 |
| Decrease in research and development rebate due | – | 253,941 |
| Increase (decrease) in accounts payable | 176,798 | (206,404) |
| Increase (decrease) in accrued wages | 215,877 | (49,870) |
| Increase in accrued interest | 98,628 | 111,660 |
| Net cash used in operating activities | (295,192) | (967,442) |
| Cash flows from investing activities: | ||
| Cash proceeds from sale of assets | – | 1,000,000 |
| Net cash provided by investing activities | – | 1,000,000 |
| Cash flows from financing activities: | ||
| Proceeds from notes payable | 300,000 | 350,000 |
| Principal payments made on notes payable | – | (274,896) |
| Interest payments made on notes payable | – | (34,007) |
| Proceeds from equity financing | – | 55,620 |
| Net cash provided by financing activities | 300,000 | 96,717 |
| Increase in cash | 4,808 | 129,275 |
| Cash: | ||
| Beginning of period | 2,379 | 36,865 |
| End of period | $7,187 | $166,140 |
| Supplemental disclosure of cash information: | ||
| Cash paid for interest | $1,758 | $34,007 |
| Supplemental disclosure of non-cash information: | ||
| Common stock issued for principal conversion of notes payable | $– | $993,872 |
| Increase in principal of notes payable | – | 60,000 |
| Shares issued for exercised warrants | – | 1,610 |
| Return of shares | – | 100 |
| Deemed dividend | – | 63,455 |
| Warrants issued in connection with debt financing | 13,343 | 28,448 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
Odyssey Health, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.